Australia's most trusted
source of pharma news
Wednesday, 16 October 2024
Posted 16 October 2024 AM
Sanofi may soon have direct competition in the atopic dermatitis market, but how the newcomer fares will depend on its strategy for differentiating itself from the market leader.
Eli Lilly has a PBAC recommendation for monoclonal antibody Interlueken 13 blocker Ebglyss, although the drug is now considered inactive in government processes. Lilly did celebrate FDA approval in September.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.